L-arginine and Brown Adipose Tissue
Maneno muhimu
Kikemikali
Maelezo
Rationale: The South Asian population originally descends from the Indian subcontinent and represents approximately 20% of the total world population. This population is facing an epidemic of type 2 diabetes, of which the underlying cause is still unknown. A high prevalence of a disadvantageous metabolic phenotype, consisting of obesity, insulin resistance and dyslipidemia, may at least in part contribute to this excess risk. It is currently hypothesized that an ethnic susceptibility towards a disturbed energy metabolism may underlie this disadvantageous metabolic phenotype. In line with this, the investigators recently discovered that Dutch South Asian subjects have 32% lower resting energy expenditure (REE) and 34% lower energy-combusting brown adipose tissue (BAT) compared to matched white Caucasians. Nitric oxide (NO) was recently shown to be crucial for BAT development and, interestingly, South Asians have diminished NO bioavailability. Thus, the disadvantageous metabolic phenotype in South Asians may be caused by diminished NO bioavailability resulting in lower BAT volume. Therefore, the investigators hypothesize that increasing NO generation in the body by administration of L-arginine, the precursor of NO, will improve their metabolic phenotype by increasing BAT volume, thereby increasing REE and clearance of triglycerides and glucose by BAT.
Objectives: The primary objectives are: 1) to determine the effect of L-arginine on glucose uptake by brown adipose tissue and to assess whether the effect differs between South Asian and white Caucasian subjects; 2) to determine the effect of L-arginine on whole body energy expenditure and to assess whether the effect differs between South Asian and white Caucasian subjects; 3) to determine the effect of L-arginine on fat mass and to assess whether the effect differs between South Asian and white Caucasian subjects.
Study design: A randomized placebo-controlled multicenter cross-over study will be performed in moderately obese Dutch South Asians and matched white Caucasians. Subjects will receive L-arginine (9 gram/day) or placebo for 6 weeks, followed by a wash-out period of 4 weeks and then again 6 weeks of one of either treatments. At the end of both treatment periods, a cold-induced PET-CT scan will be performed. Furthermore, muscle and fat biopsies will be obtained, thermoregulation will be assessed, an oral glucose tolerance will be performed and the investigators will assess NO-dependent and independent vasodilation by means of iontophoresis.
Study population: Mildly obese (BMI 25-30 kg/m2) pre-diabetic male volunteers of South Asian and white Caucasian descent aged between 35-50 years.
Intervention: The intervention will consist of administration of 9 grams of L-arginine per day in three gifts (3dd 3 gram).
Tarehe
| Imethibitishwa Mwisho: | 10/31/2014 |
| Iliyowasilishwa Kwanza: | 11/10/2014 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 11/12/2014 |
| Iliyotumwa Kwanza: | 11/13/2014 |
| Sasisho la Mwisho Liliwasilishwa: | 11/12/2014 |
| Sasisho la Mwisho Lilichapishwa: | 11/13/2014 |
| Tarehe halisi ya kuanza kwa masomo: | 10/31/2014 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 09/30/2015 |
| Tarehe ya Kukamilisha Utafiti: | 11/30/2015 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: L-arginine
Drug: Placebo
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: L-arginine Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks. | Drug: L-arginine 9 gram L-arginine / day for 6 weeks |
| Placebo Comparator: Placebo Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks. | Drug: Placebo 9 gram placebo / day for 6 weeks |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 35 Months Kwa 35 Months |
| Jinsia Inastahiki Kujifunza | Male |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Caucasian or South Asian ethnicity - Age: 35-50 years - Gender: male - BMI: 25-30 kg/m2 - Plasma glucose levels 2 h after OGTT between 7.8 and 11 mM (e.g. impaired glucose tolerance) or Fasting plasma glucose levels > 5.5 mM - Good general health Exclusion Criteria: - Type 2 diabetes (determined on basis of oral glucose tolerance test (OGTT)) - BMI > 30 kg/m2 - Plasma glucose levels 2 h after OGTT < 7.8 mM - Plasma L-arginine levels < 41 or > 114 uM - Use of beta-blockers (these inhibit BAT activity) < 1 month before start of study or during study - Systolic blood pressure < 90 mmHg - Haematocrit < 0.41 or > 0.51 l/l - Haemoglobin < 8.5 or > 11.0 - Creatinine (enzymatic method) < 45 or > 100 μmol/L - ASAT > 45 U/L - ALAT > 50 U/L - Alkaline phosphatase > 125 U/L - Gamma GT > 45 U/L - Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study - Abuse of drugs and/or alcohol - Hyperthyroidism or hypothyroidism - Participation in earlier research or medical examinations that included PET-CT scanning - Psychologically unstable subjects (as judged by the treating medical specialist) - Subjects with mental retardation (as judged by the treating medical specialist) - Subjects with severe behaviour disorders (as judged by the treating medical specialist) |
Matokeo
Hatua za Matokeo ya Msingi
1. Standard uptake value of Brown adipose tissue [6 weeks]
2. Energy expenditure [6 weeks]
3. Fat mass [6 weeks]
Hatua za Matokeo ya Sekondari
1. Body temperatures [6 weeks]
2. Skin perfusion and endothelial-dependent and independent vasodilation [6 weeks]
3. Skeletal muscle mitochondrial respiration/uncoupling [6 weeks]
4. Brown adipocyte recruitment and inflammation in WAT [6 weeks]
5. Blood parameters [6 weeks]
